drugset / Trial / NCT06927570
A Study of HS-20122 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.
Timeline
- Start
- 2025-04-15
- Primary completion
- 2028-01-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20122 | Unknown | — | Intravenous |